NASDAQ:HZNPHorizon Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Horizon Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $48.82 -1.53 (-3.04 %) (As of 06/4/2020 09:23 AM ET) Add Compare Share Today's Range$48.63Now: $48.82▼$50.4950-Day Range$30.54MA: $41.32▼$50.7352-Week Range$22.69Now: $48.82▼$50.90Volume2.44 million shsAverage Volume2.89 million shsMarket Capitalization$9.31 billionP/E Ratio17.25Dividend YieldN/ABeta1.2 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company's primary care marketed medicines comprise PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; VIMOVO for the relief of signs and symptoms of OA, RA, and AS and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and MIGERGOT, a therapy to abort or prevent vascular headaches, such as migraines and migraine variants. It has collaboration agreements with Alliance for Lupus Research, Syneos Health, Inc., and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.Read More Beat the Market (BTM) Rank™ 2.5 Analyst's Opinion Consensus RatingHorizon Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $46.92, Horizon Therapeutics has a potential downside of 3.9% from its current price of $48.82.Amount of Analyst CoverageHorizon Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.3 Community Rank Outperform VotesHorizon Therapeutics has received 833 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHorizon Therapeutics has received 422 “underperform” votes. (Add your “underperform” vote.)Community SentimentHorizon Therapeutics has received 66.37% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Horizon Therapeutics and other stocks. Vote “Outperform” if you believe HZNP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HZNP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHorizon Therapeutics does not currently pay a dividend.Dividend GrowthHorizon Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Horizon Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,939,331.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Horizon Therapeutics is held by insiders.Percentage Held by Institutions90.08% of the stock of Horizon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Horizon Therapeutics are expected to grow by 75.95% in the coming year, from $1.58 to $2.78 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Horizon Therapeutics is 17.25, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.86.Price to Earnings Ratio vs. SectorThe P/E ratio of Horizon Therapeutics is 17.25, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.88.Price to Earnings Growth RatioHorizon Therapeutics has a PEG Ratio of 1.77. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHorizon Therapeutics has a P/B Ratio of 4.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.85 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:HZNP Previous Symbol CUSIP44047T10 CIK1492426 Webwww.horizontherapeutics.com Phone011-353-1772-2100Debt Debt-to-Equity Ratio0.62 Current Ratio2.39 Quick Ratio2.27Price-To-Earnings Trailing P/E Ratio17.25 Forward P/E Ratio30.90 P/E Growth1.77 Sales & Book Value Annual Sales$1.30 billion Price / Sales7.16 Cash Flow$3.36 per share Price / Cash Flow14.51 Book Value$11.67 per share Price / Book4.18Profitability EPS (Most Recent Fiscal Year)$1.94 Net Income$573.02 million Net Margins43.06% Return on Equity22.52% Return on Assets10.37%Miscellaneous Employees1,200 Outstanding Shares190,780,000Market Cap$9.31 billion Next Earnings Date8/5/2020 (Estimated) OptionableOptionable NASDAQ:HZNP Rates by TradingView Receive HZNP News and Ratings via Email Sign-up to receive the latest news and ratings for HZNP and its competitors with MarketBeat's FREE daily newsletter. Horizon Therapeutics (NASDAQ:HZNP) Frequently Asked Questions How has Horizon Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Horizon Therapeutics' stock was trading at $30.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HZNP stock has increased by 60.0% and is now trading at $48.82. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Horizon Therapeutics? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics in the last year. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Horizon Therapeutics. When is Horizon Therapeutics' next earnings date? Horizon Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Horizon Therapeutics. How were Horizon Therapeutics' earnings last quarter? Horizon Therapeutics PLC (NASDAQ:HZNP) posted its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported $0.40 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.21 by $0.19. The biopharmaceutical company earned $355.90 million during the quarter, compared to analyst estimates of $287.88 million. Horizon Therapeutics had a return on equity of 22.52% and a net margin of 43.06%. The firm's revenue was up 26.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.30 EPS. View Horizon Therapeutics' earnings history. What guidance has Horizon Therapeutics issued on next quarter's earnings? Horizon Therapeutics updated its FY 2020 Pre-Market earnings guidance on Wednesday, May, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.4-1.45 billion, compared to the consensus revenue estimate of $1.35 billion. What price target have analysts set for HZNP? 12 equities research analysts have issued 1-year target prices for Horizon Therapeutics' shares. Their forecasts range from $35.00 to $61.00. On average, they expect Horizon Therapeutics' stock price to reach $46.92 in the next twelve months. This suggests that the stock has a possible downside of 3.9%. View analysts' price targets for Horizon Therapeutics. Has Horizon Therapeutics been receiving favorable news coverage? News coverage about HZNP stock has trended very positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Horizon Therapeutics earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutHorizon Therapeutics. Who are some of Horizon Therapeutics' key competitors? Some companies that are related to Horizon Therapeutics include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Zogenix (ZGNX) and Corcept Therapeutics (CORT). View all competitors. What other stocks do shareholders of Horizon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics investors own include Alibaba Group (BABA), Opko Health (OPK), NVIDIA (NVDA), Netflix (NFLX), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Bank of America (BAC) and Paypal (PYPL). Who are Horizon Therapeutics' key executives? Horizon Therapeutics' management team includes the following people: Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 52)Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 54)Dr. Shao-Lee Lin M.D., Ph.D., Exec. VP, Head of R&D and Chief Scientific Officer (Age 52)Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 65)Mr. Robert F. Carey, Exec. VP & Chief Bus. Officer (Age 60) What is Horizon Therapeutics' stock symbol? Horizon Therapeutics trades on the NASDAQ under the ticker symbol "HZNP." Who are Horizon Therapeutics' major shareholders? Horizon Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.40%), William Blair Investment Management LLC (4.38%), Janus Henderson Group PLC (3.50%), JPMorgan Chase & Co. (2.17%), Invesco Ltd. (1.53%) and State Street Corp (1.40%). Company insiders that own Horizon Therapeutics stock include Barry Moze, Brian K Beeler, Geoffrey M Curtis, Irina Konstantinovsky, James Samuel Shannon, Jeff Kent, Jeffrey W Sherman, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert and Vikram Karnani. View institutional ownership trends for Horizon Therapeutics. Which major investors are selling Horizon Therapeutics stock? HZNP stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, APG Asset Management N.V., APG Asset Management N.V., Invesco Ltd., William Blair Investment Management LLC, Balyasny Asset Management LLC, Two Sigma Advisers LP, and Russell Investments Group Ltd.. Company insiders that have sold Horizon Therapeutics company stock in the last year include Barry Moze, Brian K Beeler, Geoffrey M Curtis, Irina Konstantinovsky, James Samuel Shannon, Jeff Kent, Jeffrey W Sherman, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert, and Vikram Karnani. View insider buying and selling activity for Horizon Therapeutics. Which major investors are buying Horizon Therapeutics stock? HZNP stock was acquired by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Janus Henderson Group PLC, Orbimed Advisors LLC, Redwood Investments LLC, Scout Investments Inc., Samlyn Capital LLC, Carillon Tower Advisers Inc., and JPMorgan Chase & Co.. View insider buying and selling activity for Horizon Therapeutics. How do I buy shares of Horizon Therapeutics? Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Horizon Therapeutics' stock price today? One share of HZNP stock can currently be purchased for approximately $48.82. How big of a company is Horizon Therapeutics? Horizon Therapeutics has a market capitalization of $9.31 billion and generates $1.30 billion in revenue each year. The biopharmaceutical company earns $573.02 million in net income (profit) each year or $1.94 on an earnings per share basis. Horizon Therapeutics employs 1,200 workers across the globe. What is Horizon Therapeutics' official website? The official website for Horizon Therapeutics is www.horizontherapeutics.com. How can I contact Horizon Therapeutics? Horizon Therapeutics' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected] This page was last updated on 6/4/2020 by MarketBeat.com Staff
